Cargando…
RAB18 is a key regulator of GalNAc-conjugated siRNA-induced silencing in Hep3B cells
Small interfering RNA (siRNA) therapeutics have developed rapidly in recent years, despite the challenges associated with delivery of large, highly charged nucleic acids. Delivery of siRNA therapeutics to the liver has been established, with conjugation of siRNA to N-acetylgalactosamine (GalNAc) pro...
Autores principales: | Lu, Jiamiao, Swearingen, Elissa, Hardy, Miki, Collins, Patrick, Wu, Bin, Yuan, Eric, Lu, Daniel, Li, Chi-Ming, Wang, Songli, Ollmann, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035644/ https://www.ncbi.nlm.nih.gov/pubmed/35505960 http://dx.doi.org/10.1016/j.omtn.2022.04.003 |
Ejemplares similares
-
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020) -
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018) -
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017) -
GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
por: Thangamani, Lokesh, et al.
Publicado: (2021) -
Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs
por: Agarwal, Saket, et al.
Publicado: (2021)